Understanding the APOL1 Gene Variant and Its Impact on Kidney Disease in Black Americans

Every year, thousands of Black Americans are diagnosed with kidney disease. Many never learn the true reason behind their condition. They often hear it is due to high blood pressure, diabetes, or simply bad luck. While these factors can be true, for many, the underlying cause is a genetic variant known as APOL1.

Today is APOL1 Awareness Day. As a nephrologist committed to health equity, I want to explain what this gene means, who is at risk, and — most importantly — what steps you can take right now.

What Is APOL1 — And Why Does It Matter?

APOL1 stands for Apolipoprotein L1. It is a gene that everyone carries, but two specific variants, G1 and G2, are found almost exclusively in individuals of West African descent. These variants evolved thousands of years ago to protect against African sleeping sickness, a deadly parasitic infection.

KEY POINT: Evolution solved one problem — and created another. The same variants that once protected against a deadly parasite can, under certain conditions, harm the kidneys.

When a person inherits two copies of these risk variants (one from each parent), the APOL1 protein can begin to damage the kidney's filtering cells, known as podocytes. Over time, this leads to protein leaking into the urine and scarring in the kidney, resulting in a condition called FSGS (focal segmental glomerulosclerosis) and eventually kidney failure.

Who Is at Risk? The Numbers Are Striking.

APOL1 kidney disease primarily affects individuals of West African ancestry, including most African Americans. Here are some striking statistics:

| Statistic | Detail |

|-----------------------------------------|-----------------------------|

| Carry ≥1 risk variant | ~50% of African Americans |

| Carry 2 risk variants (high-risk) | ~13% of African Americans |

| People affected worldwide | Over 70 million |

| FSGS risk (vs. non-carriers) | Up to 17× higher |

| HIV-associated nephropathy risk | Up to 89× higher |

| Typical disease onset | Before age 50 |

| Earlier dialysis vs. non-carriers | ~10 years earlier |

Important: Having two risk variants does not guarantee kidney disease. Only about 15–20% of high-risk carriers will develop significant chronic kidney disease (CKD) in their lifetime. However, certain triggers can tip the balance.

What Triggers APOL1 Kidney Disease?

Think of APOL1 variants as a loaded gun. The trigger is usually a "second hit" — an external stressor that activates the gene or injures already-vulnerable podocytes.

Common triggers include:

• HIV infection: APOL1 carriers have up to 89× higher risk of HIV-associated kidney disease.

• COVID-19 infection

• Lupus flares

• Interferon-based medications: Used for hepatitis C/B, multiple sclerosis, and some blood cancers.

• Certain IV bone medications: Such as pamidronate (Aredia).

• JAK inhibitor medications and some cancer immunotherapies.

• Sustained inflammation from any cause.

  
  

DR. VYAS SAYS: If you are of African descent and need any of these medications, tell your doctor about your family history of kidney disease. That one conversation could change your care plan.

What Are the Warning Signs?

APOL1 kidney disease often remains silent until it is advanced. The earliest signs can be subtle and easily overlooked:

• Foamy or bubbly urine — this indicates protein leaking from the kidneys.

• Swelling in the legs, ankles, or around the eyes.

• High blood pressure that is difficult to control.

• Unexplained fatigue.

• An abnormal kidney function test (creatinine, eGFR) found on routine bloodwork.

  
  

If you or a family member of African descent experiences any of these signs — especially without diabetes — please consult your doctor about a kidney evaluation.

Frequently Asked Questions

Q: Should I get tested for APOL1?

This is a common question. The honest answer is: it depends. Currently, major kidney disease organizations like KDIGO do not recommend routine genetic screening for the general population. However, testing may be beneficial in certain situations:

• You are of African ancestry with protein in your urine and no diabetes.

• You have been diagnosed with FSGS or unexplained kidney disease.

• You are being evaluated as a living kidney donor.

• You have a family history of early kidney failure (before age 60).

• You may be eligible for a clinical trial for targeted APOL1 therapy.

  
  

Genetic counseling is recommended before testing. A positive result carries real emotional weight and complex implications — especially given incomplete penetrance.

Q: How is APOL1 kidney disease treated?

Currently, there is no FDA-approved treatment specifically targeting APOL1 kidney disease. However, effective tools exist for slowing progression:

• ACE inhibitors or ARBs: Blood pressure medications that also protect the kidneys and reduce proteinuria. These are the cornerstone of treatment.

• SGLT2 inhibitors (empagliflozin, dapagliflozin): Originally developed for diabetes, now proven to slow kidney disease progression broadly.

• Tight blood pressure control: Critical, since hypertension significantly accelerates APOL1 kidney disease.

• Removal of second-hit triggers: Stopping an offending medication or treating HIV can sometimes lead to partial or full recovery.

  
  

Note: Steroids and conventional immunosuppressants have limited efficacy in APOL1-driven FSGS and carry significant side effects. Knowing your genotype can genuinely change the treatment approach.

Q: Is there anything new on the horizon?

Yes — and this is genuinely exciting. The research landscape for APOL1 kidney disease is advancing rapidly. Three therapies are currently in active clinical development:

| Therapy | How It Works | Stage | Key Result |

|--------------------------------|------------------------------------------------------|-------------------------------|----------------------------------------------|

| Inaxaplin (VX-147) | Blocks APOL1 protein's toxic channel activity in podocytes | Phase 2–3 Trial (NCT05312879) | 47.6% reduction in proteinuria at 13 weeks |

| APOL1 ASO (IONIS-APOL1Rx) | Reduces the body's production of APOL1 mRNA/protein | Preclinical / Early Clinical | Prevented proteinuria in transgenic mouse models |

| Baricitinib (JAK1/2 inhibitor) | Blocks the signaling pathway that activates APOL1 gene expression | Phase 2 — JUSTICE Trial (NCT05237388) | Enrolling; 41% UACR reduction seen in related CKD model |

WHAT THIS MEANS: If any of these therapies receive FDA approval, APOL1 genotyping will likely become standard practice. You will need to know your genotype to qualify for treatment. Getting tested when appropriate puts you ahead of the curve.

Q: What if I am considering donating a kidney?

APOL1 genotype matters significantly in this context. Kidneys from deceased donors with two APOL1 risk variants fail 2–4 times more rapidly after transplant. If you are of African descent and are being evaluated as a living kidney donor, please discuss APOL1 genotyping with your transplant team. This information protects both you and your recipient.

A Message for This Awareness Day

Awareness is the first step toward equity. APOL1 kidney disease is not a result of bad choices or poor compliance. It is a genetic predisposition carried by millions of Black Americans, disproportionately burdening a community that already faces significant health disparities.

My mission at Kidney MD is to ensure that every patient — regardless of background — has access to the knowledge and care they deserve. If you have questions about your kidney health, your family history, or whether APOL1 testing is right for you, I am here.

— Dr. Ritu R. Vyas, MD | KidneyMD LLC | Catonsville, MD | (443) 380-0120 | kidneymd.net

Concerned about your kidney health?

Schedule a consultation at Kidney MD in Catonsville, MD.

📞 (443) 380-0120   |   🌐 kidneymd.net

Disclaimer: This post is for educational purposes only and does not constitute medical advice. Please consult your physician or a board-certified nephrologist for personalized guidance.